Kromek Regulatory News (KMK)

5 June 2023

Kromek Group plc 

("Kromek" or the "Group") 

New $1.5m CBRN contract in Asia

Contract for the supply of a new product for civil nuclear applications

Kromek Group plc (AIM: KMK), a leading developer of radiation and bio-detection technology solutions for the advanced imaging and CBRN detection segments, is pleased to announce that it has secured a contract worth $1.5m in the civil nuclear market, which is to be delivered over the next 15 months.

The contract has been awarded by one of the Group's distribution partners in Asia and is to supply three new end customers in the region. Importantly, the order is for a new product, based on the Group's existing technology, with the development of the product having been funded by the distribution partner. The product is designed for civil nuclear applications, including the detection, identification and analysis of radiological sources.

Arnab Basu, CEO of Kromek Group, said: "It is great to have received our first order for this new product line as we commence the commercialisation phase. It reflects the strength of our business model as another example of customer-funded development work transitioning to a product delivery phase. It is also indicative of the increasing interest that we are receiving in our CZT-based technology in the fast-growing Asian markets. We look forward to receiving additional orders for this product line and continuing to expand our reach in Asia."

For further information, please contact: 

Kromek Group plc 

Kromek Group plc is a leading developer of radiation detection and bio-detection technology solutions for the advanced imaging and CBRN detection segments. Headquartered in County Durham, UK, Kromek has manufacturing operations in the UK and US, delivering on the vision of enhancing the quality of life through innovative detection technology solutions.  

The advanced imaging segment comprises the medical (including CT and SPECT), security and industrial markets. Kromek provides its OEM customers with detector components, based on its core cadmium zinc telluride (CZT) platform, to enable better detection of diseases such as cancer and Alzheimer's, contamination in industrial manufacture and explosives in aviation settings.  

In CBRN detection, the Group provides nuclear radiation detection solutions to the global homeland defence and security market. Kromek's compact, handheld, high-performance radiation detectors, based on advanced scintillation technology, are primarily used to protect critical infrastructure and urban environments from the threat of 'dirty bombs'.  

The Group is also developing bio-security solutions in the CBRN detection segment. These consist of fully automated and autonomous systems to detect a wide range of airborne pathogens.  

Kromek is listed on AIM, a market of the London Stock Exchange, under the trading symbol 'KMK'.  

Further information is available at www.kromek.com.